research Integration of Point-of-Care Technology in the Decoding Process of Single Nucleotide Polymorphism for Healthcare Application †
Portable point-of-care testing can improve quick and accurate genetic disorder detection.
Search
for
Sort by
Research
150-180 / 1000+ results
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Docking-based workflow and ADME prediction of some compounds in Curcuma longa and Andrographis paniculata as polymerase PA-PB1 inhibitors of influenza A/H5N1 virus
Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
research RESPOSTA TERAPÊUTICA DA ALOPÉCIA ANDROGENÉTICA APÓS DRUG DELIVERY DIGITAL COM APLICAÇÃO DE PRODEW 500®, NANOFACTOR® AFGF, NANOFACTOR® VEGF, COPPER PEPTÍDEO®, PROHAIRIN B4®, CAPILLISIL HC® E ARCT-ALG®
The document does not give specific results for hair loss treatment effectiveness.
research Expansion of the spectrum of ITGB6-related disorders to adolescent alopecia, dentogingival abnormalities and intellectual disability
A rare ITGB6 gene variant causes intellectual disability, hair loss, and dental issues.
research 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research S2594 Autoimmune Hepatitis Due to Para-Aminobenzoic Acid
Para-aminobenzoic acid in hair supplements can cause autoimmune hepatitis.
research Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Alopecia Areata Following the Use of Belimumab in a Patient with Systemic Lupus Erythematosus and Arthritis Who Responded Well to Baricitinib: A Case Report
Baricitinib improved hair loss and arthritis in a lupus patient.
research Crystallization and preliminary X-ray analysis of the human androgen receptor ligand-binding domain with a coactivator-like peptide and selective androgen receptor modulators
Scientists successfully created and analyzed the structure of a part of the human androgen receptor with specific modulators and a peptide to understand how it binds differently in various tissues.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
research The Diameter Factor of Aligned Membranes Facilitates Cutaneous Wound Healing by Promoting Epithelialization in an Immune Way
A300 membranes help skin heal faster by promoting cell growth and repair.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research A liquid chromatography/tandem mass spectrometry method for determination of aristolochic acid‐I in rat plasma
A reliable method was developed to measure aristolochic acid-I in rat blood.
research Baricitinib as a treatment for myasthenia gravis: A case report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
This review highlights the effectiveness of Janus kinase (JAK) inhibitors in treating alopecia areata (AA), an autoimmune condition causing hair loss. JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib have shown significant hair regrowth by blocking cytokine signaling pathways. Clinical trials such as BRAVE-AA1/2 and ALLEGRO-2a/2b/3 reported substantial improvements, with baricitinib achieving SALT scores ≤20 in up to 40.9% of patients. Tofacitinib and ruxolitinib, used off-label, also demonstrated promising results. However, AA recurrence is common after stopping treatment. While JAK inhibitors are promising, they require ongoing research to optimize treatment and manage potential adverse events.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research A new mutation Rim3 resembling Re den is mapped close to retinoic acid receptor alpha (Rara) gene on mouse Chromosome 11
research Green approach for the recovery of secondary metabolites from the roots of Nardostachys Jatamansi (D. Don) DC using microwave radiations: Process optimization and anti-alzheimer evaluation
Microwave extraction is an effective, eco-friendly way to boost N. jatamansi's anti-Alzheimer's properties.
research Film-trigger applicator (FTA) for improved skin penetration of microneedle using punching force of carboxymethyl cellulose film acting as a microneedle applicator
The film-trigger applicator improves microneedle skin delivery and drug efficiency using simple finger force.
research Design of a RADA16-based self-assembling peptide nanofiber scaffold for biomedical applications
RADA16 is a promising material for tissue repair and regenerative medicine but needs improvement in strength and cost.
research Supramolecular Adenosine-Based Skin Delivery System for Hair Regulation and Restoration
TA-Ado effectively promotes hair growth and reduces hair loss.